Aurograb
Alternative Names: AurograbLatest Information Update: 02 Sep 2008
At a glance
- Originator NeuTec Pharma
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 29 Aug 2008 Discontinued - Phase-II for Meticillin-resistant Staphylococcus aureus infections in European Union (IV)
- 14 Jul 2006 NeuTec Pharma has been acquired by Novartis
- 16 Jun 2006 NeuTec Pharma has completed a phase III trial for Meticillin-resistant Staphylococcus aureus in Europe